Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 75 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Bobos, Mattheos  [Clear All Filters]
2016
Fountzilas, E., Kotoula V., Zagouri F., Giannoulatou E., Kouvatseas G., Pentheroudakis G., et al. (2016).  Disease evolution and heterogeneity in bilateral breast cancer.. Am J Cancer Res. 6(11), 2611-2630.
Kotoula, V., Karavasilis V., Zagouri F., Kouvatseas G., Giannoulatou E., Gogas H., et al. (2016).  Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.. Breast Cancer Res Treat. 158(2), 307-21.
Lakis, S., Dimoudis S., Kotoula V., Alexopoulou Z., Kostopoulos I., Koletsa T., et al. (2016).  Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer.. Anticancer Res. 36(5), 2365-78.
Gogas, H., Kotoula V., Alexopoulou Z., Christodoulou C., Kostopoulos I., Bobos M., et al. (2016).  MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.. J Transl Med. 14(1), 136.
Fountzilas, G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., et al. (2016).  TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.. Oncotarget. 7(22), 32731-53.
Hatzibougias, D. I., Fouzas I., Bobos M., Papanikolaou V., Daoudaki M., Kotoula V., et al. (2016).  Tubular Pyloric Gland Adenoma of the Left and Right Hepatic Ducts: Report of a Unique Case With Immunohistochemical and Molecular Studies.. Int J Surg Pathol. 24(4), 347-52.
Kotoula, V., Chatzopoulos K., Lakis S., Alexopoulou Z., Timotheadou E., Zagouri F., et al. (2016).  Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.. Oncotarget. 7(4), 5074-87.
2015
Koutras, A., Kalogeras K. T., Wirtz R. M., Alexopoulou Z., Bobos M., Zagouri F., et al. (2015).  Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.. J Transl Med. 13, 171.
Kourea, H. P., Kotoula V., Koutras A., Alexopoulou Z., Papaspirou I., Skarlos D. V., et al. (2015).  Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study.. Histol Histopathol. 30(9), 1129-41.
Kotoula, V., Bobos M., Vassilakopoulou M., Tsolaki E., Chrisafi S., Psyrri A., et al. (2015).  Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC).. Appl Immunohistochem Mol Morphol. 23(1), 60-70.
Pavlakis, K., Bobos M., Batistatou A., Kotoula V., Eleftheraki A. G., Stofas A., et al. (2015).  p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.. Pathol Oncol Res. 21(2), 273-82.
Koumarianou, A., Karayannopoulou G., Gourgioti G., Batistatou A., Bobos M., Efstratiou I., et al. (2015).  PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.. Cancer Chemother Pharmacol. 75(6), 1289-301.
2014
Kotoula, V., Bobos M., Alexopoulou Z., Papadimitriou C., Papadopoulou K., Charalambous E., et al. (2014).  Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.. PLoS One. 9(8), e103707.
Koletsa, T., Stavridi F., Bobos M., Kostopoulos I., Kotoula V., Eleftheraki A. G., et al. (2014).  alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies.. BMC Clin Pathol. 14, 28.
Lakis, S., Kotoula V., Eleftheraki A. G., Batistatou A., Bobos M., Koletsa T., et al. (2014).  The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping.. Breast. 23(3), 234-43.
Razis, E., Pentheroudakis G., Rigakos G., Bobos M., Kouvatseas G., Tzaida O., et al. (2014).  EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.. J Cancer Res Clin Oncol. 140(5), 737-48.
Kalogiannidis, I., Petousis S., Bobos M., Margioula-Siarkou C., Topalidou M., Papanikolaou A., et al. (2014).  HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma.. Arch Gynecol Obstet. 290(6), 1231-7.
Vassilakopoulou, M., Togun T., Dafni U., Cheng H., Bordeaux J., Neumeister V. M., et al. (2014).  In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.. PLoS One. 9(6), e99131.
Tirodimos, I., Bobos M., Kazakos E., Haidich A-B., Dardavessis T., Kostopoulos I., et al. (2014).  Molecular detection of Helicobacter pylori in a large Mediterranean river, by direct viable count fluorescent in situ hybridization (DVC-FISH).. J Water Health. 12(4), 868-73.
Koumarianou, A., Tzeveleki I., Mekras D., Eleftheraki A. G., Bobos M., Wirtz R., et al. (2014).  Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.. Anticancer Res. 34(9), 4949-62.
Psyrri, A., Kotoula V., Fountzilas E., Alexopoulou Z., Bobos M., Televantou D., et al. (2014).  Prognostic significance of the Wnt pathway in squamous cell laryngeal cancer.. Oral Oncol. 50(4), 298-305.
Krikelis, D., Kotoula V., Bobos M., Fountzilas E., Markou K., Karasmanis I., et al. (2014).  Protein and mRNA expression of notch pathway components in operable tumors of patients with laryngeal cancer.. Anticancer Res. 34(11), 6495-503.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.